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Abstract
Background: There is no information regarding the resistance mechanisms of extended-spectrum ß-lactamase
(ESBL)-producing Enterobacteriaceae in community setting in Cameroon. The current study aimed to determine the
proportion of ESBLs in Enterobacteriaceae isolated in the community and to analyse some risk factors associated
with ESBL carriage.
Methods: Faecal samples were collected from 208 different outpatients and 150 healthy student volunteers
between 3 January and 3 April 2009. Enterobacterial isolates resistant to third-generation cephalosporins were
screened for ESBL production by the double-disk synergy test. Presumptive ESBL-producing isolates with positive
synergy test were identified by Mass Spectrometry using the BioTyper MALDI-TOF. For such ESBL positive isolates,
antibiotic susceptibility was determined by the Vitek 2 system. PCR and sequencing were performed for the
detection of different types of ESBL genes in presumptive ESBL-producing isolates. Statistical methods were used
for the univariate calculation of risk factors.
Results: During the study period, a total of 358 faecal samples were analysed; 58 of such samples (16%) showed an
ESBL phenotype and were confirmed by PCR. The proportion of ESBL producers in faecal carriage was statistically
different between outpatients and student volunteers (23.1% vs. 6.7%: p < 0.000). According to a univariate analysis,
previous use of antibiotics (ciprofloxacin) appeared to be a risk factor for ESBL carriage (p < 0.05).
Escherichia coli was the species most frequently isolated among the ESBL producers in outpatients (66.7%) and student
volunteers (90%). Isolates showed additional resistance to gentamicin, ciprofloxacin and trimethoprim/sulfamethoxazole
but none of them was resistant to temocillin, amikacin or meropenem. Most of the strains (97%) produced a CTX-M
group 1 enzymes [CTX-M-15 (98%) or CTX-M-1 (2%)] and the remaining strains produced SHV-12 enzyme (3%).
Conclusions: The use of drugs such as amoxicillin, ciprofloxacin and trimethoprim/sulfamethoxazole does not
seem appropriate for empirical treatment because of emerging resistance. The implementation in Cameroon or in
other African countries of methods of screening ESBL-producing organisms in routine laboratories is of great
importance in order for us to offer patients appropriate treatment and for infection control efforts to succeed.
Background
S i n c et h ee a r l y1 9 8 0 s ,t h i r d - generation cephalosporins
have become an important tool in the treatment of severe
bacterial infections. Unfortunately, extended-spectrum
ß-lactamases (ESBLs), responsible for resistance against
almost all penicillins, cephalosporins (except cephamy-
cins), and other monobactams, have been acquired by a
great number of bacterial species [1]. ESBL-producing
Enterobacteriaceae have been responsible for many local,
national and international outbreaks and have become a
serious problem in hospitalized patients [2]. Recent stu-
dies suggest that ESBL-producing Enterobacteriaceae
should not be considered as exclusively nosocomial
pathogens. ESBL-producing Enterobacteriaceae have
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any medium, provided the original work is properly cited.been reported to cause urinary tract infections and bac-
teraemia in outpatients [2,3]. Since 2001, reports of com-
munity-acquired infections caused by ESBL-producing
Enterobacteriaceae have emerged worldwide [3-12].
However, in African countries, data remain scarce; only a
few studies have been conducted in community or hospi-
tal settings during nonoutbreak situations [4,13-16].
A study in Egypt found a proportion of 11% of ESBL-
producing Enterobacteriaceae in a community setting
[17], while a study in South Africa found a proportion of
7% [18]. In Cameroon, previous reports of SHV-12 and
CTX-M-15 have been described [13,16]. The proportion
of ESBLs in Enterobacteriaceae isolated from inpatients
at Yaounde Central Hospital in Cameroon between 1995
a n d1 9 9 8w a sf o u n dt ob e1 2 %[ 1 3 ] .H o w e v e r ,n os t u d y
on extended-spectrum ß-lactamase (ESBL)-producing
Enterobacteriaceae has been performed in the commu-
nity. As the first survey of its kind in Cameroon, the cur-
rent study was conducted to determine the proportion of
ESBLs in Enterobacteriaceae isolated in the community
and to analyse some risk factors associated with ESBL
carriage.
Methods
Study design
This study was conducted in the town of Ngaoundere,
the capital of the Adamawa Province in Cameroon. In
this part of the country, the main language is “Fulfulde”
and the French language dominates as the language of
instruction in schools. We were assisted in our interviews
with patients by laboratory technicians who were suitably
trained to conduct interviews. During a period of 3
months (between 3 January and 3 April 2009), a total of
358 faecal samples were collected from two population
groups: 208 outpatients (who visited the bacteriology
laboratory of Ngaoundere Protestant Hospital with a
stool sample requested by their general practitioner) and
150 healthy student volunteers (the student volunteers at
t h eU n i v e r s i t yo fN g a o u n d e r ew e r ea t t e n d i n gt h ec l i n i c
for their annual medical examination. The volunteer sub-
jects were provided with containers to collect their stool
a n dw e r et o l dt ob r i n gaf r e s hs a m p l e ,p r e f e r a b l yc o l -
lected and delivered to the laboratory within a day). Of
the outpatients, 6% had come for a planned medical visit
and 13% were suffering from acute gastroenteritis. How-
ever, for 81% of the outpatients, there was insufficient
information included in the patient record to enable us
to define the exact reason for the consultation.
All samples were collected and refrigerated until pro-
cessing. A questionnaire was designed and used to
obtain demographic information and clinical data on the
patient (age, gender, antibiotic treatment during the past
3 months and any hospital stays in the previous year).
Detection of ESBL-producing isolates in faecal samples
A total of 0.5 g of each faecal sample was suspended in
5 mL of sterile saline, and aliquots of 50 μlw e r es t r e a k e d
onto two selective media, Drigalski and MacConkey
agars, supplemented respectively with cefotaxime
(1.5 mg/L) and ceftazidime (2 mg/L), enabling the detec-
tion of Gram-negative bacteria resistant to these antibio-
tics. Plates were incubated for 24 h at 35°C. One colony
representing each distinct colonial morphotype was sub-
cultured on MacConkey agar plates and was analysed
further. All isolates that showed growth were screened
for ESBL production by using both the resistance pheno-
type and the combined double-disk synergy test with
conventional amoxicillin/clavulanate (10 μgo fc l a v u l a n i c
acid), 30 μg cefotaxime, 30 μg ceftazidime and 30 μg
cefepime disks (BBL, USA), which were applied at a
30 mm distance from amoxicillin/clavulanate [19].
Identification and antimicrobial susceptibility testing
Only the isolates with a positive synergy test - the “pre-
sumptive ESBL producers” -w e r ei d e n t i f i e db yM a s sS p e c -
trometry using the BioTyper MALDI-TOF (Bruker). For
such ESBL positive isolates, antibiotic susceptibility to the
following drugs was determined with the Vitek 2 system
(bioMérieux, France): temocillin, meropenem, amikacin,
gentamicin, ciprofloxacin, nitrofurantoin and trimetho-
prim/sulfamethoxazole. The results enabled us to define
the isolates as being susceptible or resistant according to
the criteria recommended by the Clinical and Laboratory
Standards Institute [20]. All the presumptive ESBL produ-
cers were further analysedb yP C Ra i m e da td e t e c t i n g
ESBL genes (one isolate of each morphotype from each
patient).
Automated DNA isolation
Bacteria were grown overnight on a MacConkey agar
plates at 35°C. Subsequently, colonies were picked up
using a sterile 1 μl plastic loop and transferred into 400 μl
sterile water. Total DNA was extracted with the Maxwell
automat (Promega, USA) according to the manufacturer’s
protocol. DNA was eluted in a final volume of 200 μl. The
extracted DNA was stored at -70°C for further analysis.
PCR detection and sequencing of ESBLs
All isolates were initially screened for the presence of
blaTEM, blaSHV and blaOXA-like genes using a multiplex
PCR protocol previously described by Dallenne et al.
[21]. All isolates were further screened for the presence
of blaCTX-M carrying genes belonging to the CTX-M
groups (i.e. CTX-M group1, 2, 8, 9 and 25) using a sim-
plex PCR according to a previously published method
[22]. Specific PCR amplification and DNA sequencing of
the PCR products were used to determine whether the
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sent and to characterize the type of ß-lactamase belong-
ing to each familiy. PCR products (multiplex and
simplex PCR) were visualized after electrophoresis at
100 V for 1 h on a 2% agarose gel containing ethidium
bromide. A 100 bp DNA ladder (Promega, USA) was
used as a marker size. PCR products were purified using
the Wizard
® kit (Promega, USA) and sequenced using a
3100 ABI Prism Genetic Analyser (Applied Biosystems).
Sequence alignment and analyses were performed online
using the BLAST program available at the National
Center for Biotechnology Information web page http://
www.ncbi.nlm.nih.gov.
Statistical analysis
Data was analysed with Epi Info version 3.5.3 (Centers
for Disease Control and Prevention, Atlanta, GA, USA).
We used conditional logistic regression analysis for the
univariate calculation of risk factors and odds ratios
(OR) with 95% confidence intervals (CI). A value of p <
0.05 was considered to be statistically significant. MIC
analyses were carried out using the WHONET 5 soft-
ware (World Health Organization, Geneva, Switzerland).
Ethical clearance
The study was approved by the ethics committee of the
University of Liège. The protocol was reviewed and
accepted by the authorities of the hospitals in Cameroon
(this allowed us to conduct our study). Informed con-
sent was obtained from all patients before enrolment.
Results
Characteristics of the population
The mean age of the 208 outpatients was 36.9 ± 5.1
years; of these, 88 (42%) were male. The mean age of
the student volunteers was 24.7 ± 7.3 years and
99 (66%) of these were male.
Of the outpatients, 16 (8%) had been hospitalized in
the previous year and 44/208 (21%) had received anti-
biotics within the 3 months prior to inclusion in the
study: 16 (36%) had received amoxicillin, 19 (43%)
ciprofloxacin and the remaining 9 (21%) had received
other antibiotics. Among the student volunteers, a single
student had been hospitalized in the previous year and
15 (10%) patients had received antibiotics within the 3
months before sampling: 7 (47%) had received amoxicil-
lin, 2 (13%) ciprofloxacin and the remaining 6 (40%)
had received other antibiotics (see Table 1).
Proportion of ESBL producers
During the study period, a total of 358 stool samples
from outpatients and student volunteers were analysed;
58 of such samples (16%) contained isolates (1 isolate per
patient) which grew on both selective media and were
“presumptive ESBL producers”.O ft h e5 8i s o l a t e s ,4 8
were recovered from outpatients and 10 from student
volunteers. All presumptive ESBLs were confirmed as
ESBL producers by PCR. The proportion of ESBL-produ-
cing Enterobacteriaceae in outpatients was 23.1% (48/
208) and 6.7% (10/150) in student volunteers. The pro-
portion of ESBL producers in faecal carriage was statisti-
cally different between outpatients and student
volunteers (23.1% vs. 6.7%: p < 0.000). A univariate analy-
sis comparing subjects’ ESBL positive and negative iso-
lates identified no specific factor as being associated with
ESBL carriage in both populations (Table 2). However,
the previous use of antibiotics was different for both
populations (p < 0.000) and the previous use of ciproflox-
acin appeared to be a risk factor for ESBL carriage (p <
0.05) (Table 3).
Bacterial identification and antimicrobial susceptibility
For outpatients, the most frequent species isolated
among the ESBL producers was Escherichia coli (66.7%),
followed by Enterobacter cloacae (18.8%), Citrobacter
freundii (10.4%) and Klebsiella pneumoniae (4.2%).
Among student volunteers,o ft h e1 0E S B L - p r o d u c i n g
strains, 9 were Escherichia coli (90%) and 1 strain was
Klebsiella pneumoniae (10%).
Antibiotic susceptibility was determined for 7 agents.
All isolates were susceptible to temocillin, meropenem
and amikacin. Isolates remained susceptible to nitrofur-
antoin (the percentage of sensitivity of the strains was
65%). However, isolates were frequently resistant to gen-
tamicin, ciprofloxacin and trimethoprim/sulfamethoxa-
zole with a high MIC90 value (Table 4).
Table 1 Characteristics of the 358 patients included in
the study
Characteristics Outpatients
N = 208 (%)
Student volunteers
N = 150 (%)
Age (Mean, SD) 36.9,15.12 24.7,7.3
Male gender 88 (42) 99 (66)
Hospitalization (in previous year)
yes 16 (8) 1 (1)
no 91 (44) 149 (99)
unknown 101 (48) 0
Antibiotic use (< 3 months)
yes 44 (21) 15 (10)
no 48 (23) 132 (88)
unknown 116 (56) 3 (2)
Antibiotics used
amoxicillin 14 7
ciprofloxacin 19 2
Trimethroprim/sulfamethoxazole 5 /
Other drugs 6 6
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All isolates defined as “presumptive ESBL producers”
were confirmed as ESBL producers by PCR-sequencing
of ESBL genes. Most of the strains (97%) produced a
CTX-M group 1 enzymes [CTX-M-15 (98%) or CTX-
M-1 (2%)]. The CTX-M-15 gene was detected alone
(20%) or in association with other ß-lactamase genes:
O X A - 1a n dT E M - 1( 4 5 % ) ,T E M - 1a n dS H V - 1( 4 % ) ,
TEM-1 alone (18%), OXA-1 alone (13%); while, CTX-
M-1 gene was associated with TEM-1 ß-lactamase gene.
The ESBL SHV-12 (3%) was found in two strains (1
Citrobacter freundii and 1 Escherichia coli) (Table 5).
Discussion
ESBL-producing Enterobacteriaceae have emerged
worldwide and have been reported recently in outpati-
ents in many countries. However, in African countries,
data on extended-spectrum ß-lactamase (ESBL)-produ-
cing Enterobacteriaceae are scarce. In Cameroon, since
the previous reports of SHV-12 and CTX-M-15 in 2005
[13,16], there were no other reports on the subject in
the country and there is no available information
regarding the resistance mechanisms of extended-spec-
trum ß-lactamase (ESBL)-producing Enterobacteriaceae
in the community. This study determines the proportion
of ESBL-producing Enterobacteriaceae in the commu-
nity and analyses some risk factors associated with ESBL
carriage. In this study, the proportion of faecal carriage
of ESBL-producing Enterobacteriaceae among outpati-
ents was 23.1%; this is higher than that observed among
student volunteers (6.7%), p < 0.000. This value is even
higher than those reported in Spain (5.5% in outpatients
and 3.7% in healthy volunteers) [5], in China (6.5% in
outpatients) [6] and in Saudi Arabia (13.7% in outpati-
ents) [8]. Many factors have been found to contribute to
such high rates of resistance in developing countries.
These include: poor drug quality or inadequate posol-
ogy, the long-term treatments, misuse of antibiotics by
health professionals, unskilled practitioners, auto medi-
cation (antibiotics can be purchased without prescrip-
tion), unhygienic conditions accounting for the spread
of resistant bacteria and inadequate surveillance pro-
grams [4,23].
Our study also showed high resistance rates to genta-
micin, ciprofloxacin and trimethoprim/sulfamethoxazole
but none of the isolates was resistant to temocillin, ami-
kacin or meropenem. Very similar results have been
previously found in Cameroon from outpatients and
inpatients [24] and in other countries: Morocco [25],
Benin [14], Tanzania [15], Ethiopia [26], England [27]
and Canada [28].
In addition, the majority of outpatients in this study
had been treated with amoxicillin and ciprofloxacin
within 3 months prior to inclusion in the study (Table 1).
Drugs such as amoxicillin, ciprofloxacin and trimetho-
prim/sulfamethoxazole represent the first-line antibiotics
commonly used by patients without prescription. The
presence of ESBL-producing bacteria complicates the
selection of antibiotics used for empirical therapy. Other
drugs such as temocillin, amikacin or meropenem, which
should represent the first-line treatment for infections
with ESBL-producing Enterobacteriaceae, are very expen-
sive and difficult for the population to obtain in Camer-
oon. As the available treatment options are limited,
antibiotic control policies, together with the implementa-
tion of infection control measures, remain therefore of
high importance.
In our study, the previous use of fluoroquinolone
(ciprofloxacin) appeared to have been a risk factor for
ESBL carriage (p < 0.05). Fluoroquinolones are potent
antimicrobials; they have been in clinical use for the last
two decades and have been the most commonly
Table 2 Analysis of risk factors for ESBL carriage in univariate analysis
Outpatients Student volunteers
Covariate ESBL-positive ESBL-negative P value ESBL-positive ESBL-negative P value
(n = 48) (n = 160) (n = 10) (n = 140)
Age (Mean, SD) 37.6,15.5 36.7,15 0.744 27.2,8.9 24.5,7.1 0.284
Male gender 21 67 0.817 7 92 0.782
Antibiotic use (< 3 months)
yes/no 11/8 33/40 0.212 1/9 14/123 0.982
Hospitalization (previous year)
yes/no 4/17 12/74 0.544 0/10 1/139 /
Table 3 Univariate analysis of antibiotics used among
outpatients and student volunteers
Risk factors Outpatients Student
volunteers
P value
Previous use of antibiotics
yes/no 44/48 15/132 0.000
Previous use of ciprofloxacin
yes/no 19/25 2/13 0.037
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An association between the increase in quinolone pre-
scriptions and an increase in bacterial resistance has been
reported from several different countries [29,30].
Although, in our study, there were no much records of
recent hospitalization or antibiotic consumption among
the student volunteers, we found a significant proportion
of ESBL-producing bacteria in their faecal flora. For these
students, many are likely to have been exposed to multi-
ple courses of antibiotics due to the unrestricted or over-
the-counter availability of antibiotics in developing
countries [8]. In addition, the increasing prevalence of
ESBL producers in the community increases the risk that
other individuals will become carriers as a consequence
of human-to-human transmission of resistant bacteria or
through the environment as well [31].
In the present study, Escherichia coli was the most
frequent species isolated from both outpatients and stu-
dent volunteers representing 66.7% and 90% of all iso-
lates, respectively. CTX-M-type enzymes represented
97% of ESBLs detected. CTX-M-15 was predominant
and was found to be the most frequent blaESBL present
Table 4 Antimicrobial susceptibility of ESBL-producing strains
Minimal inhibitory concentration (μg/ml)*
Name of antibiotic Citrobacter freundii (n =
5)
Enterobacter cloacae (n =
9)
Escherichia coli (n =
41)
Klebsiella pneumoniae( n=
3)
%R MIC90 %R MIC90 %R MIC90 %R MIC90
Temocillin 0 2 0 2 0 16 0 8
Meropenem 0 .125 0 .125 0 .125 0 .125
Amikacin 0 16 0 4 0 4 0 1
Gentamicin 100 32 100 32 61 32 100 32
Ciprofloxacin 100 8 75 8 75.6 8 67 8
Nitrofurantoin 0 64 33.3 64 34.1 128 67 256
Trimethoprim/Sulfamethoxazole 100 256 100 256 97.5 256 100 256
* R: resistant isolates
Table 5 Characterization of ESBL producers among 58 strains isolated from outpatients and student volunteers in
faecal flora
No. of ESBL
producers (%)
Positive genes detected by multiplex and simplex PCR
assays (no. of isolates)
ESBL (no. of
isolates)
Other ß-lactamase
genes
Outpatients
Citrobacter
freundii
5 (10.4) TEM, OXA-1-like, CTX-M (3) CTX-M-15 (3) TEM-1, OXA-1
TEM, CTX-M (1) CTX-M-15 (1) TEM-1
TEM, SHV(1) SHV-12 (1) TEM-1
Enterobacter
cloacae
9 (18.8) TEM, OXA-1-like, CTX-M (9) CTX-M-15 (9) TEM-1, OXA-1
Escherichia coli 32 (66.7) CTX-M (10) CTX-M-15 (10) None
TEM, CTX-M (8) CTX-M-15 (7) TEM-1
CTX-M-1 (1) TEM-1
OXA-1-like, CTX-M (7) CTX-M-15 (7) OXA-1
TEM, OXA-1-like, CTX-M (6) CTX-M-15 (6) TEM-1, OXA-1
SHV (1) SHV-12 (1) None
Klebsiella
pneumoniae
2 (4.2) CTX-M (1) CTX-M-15 (1) None
TEM, SHV, CTX-M (1) CTX-M-15 (1) TEM-1, SHV-1
Student
volunteers
Escherichia coli 9 (90) TEM, OXA-1-like, CTX-M (7) CTX-M-15 (7) TEM-1, OXA-1
TEM, CTX-M (2) CTX-M-15 (2) TEM-1
Klebsiella
pneumoniae
1 (10) TEM, SHV, CTX-M (1) CTX-M-15 (1) TEM-1, SHV-1
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freundii and Klebsiella pneumoniae. These findings sup-
port the evidence of the dissemination of blaCTX-M-15 in
community setting. Widespread dissemination of CTX-
M-15 has been described previously in Cameroon
among hospitalized patients [16] and in other places:
Portugal [32], Spain [33], England [9], the United States
[10], Latin America [11] and China [12]. The strains in
our study that produced CTX-M-15 genes were also co-
produced TEM-1 and OXA-1 ß-lactamase genes. These
results are consistent with previous studies from Canada
[28] and France [34]. We also identified type SHV-12 in
Escherichia coli and Citrobacter freundii.T h i se n z y m e
has risen to prominence in recent years and has been
detected in different species of Enterobacteriaceae in
many parts of the world [5].
Our study has some limitations. Firstly, we did not
screen the ESBL positive isolates for the presence of the
human pandemic O25:H4-ST131 clonal group. These
investigations have now been planned for a future study.
Secondly, it would also be interesting to take the study
further by investigating the molecular characteristics of
the different bacteria studied in order to better under-
stand the spread of resistant bacteria.
Finally, due to some missing data from the question-
naires (some patients subjects did not recall the
requested information), not all patients were included in
the respective statistical analyses of the different para-
meters studied.
Conclusions
The use of drugs such as amoxicillin, ciprofloxacin and tri-
methoprim/sulfamethoxazole does not seem appropriate
for empirical treatment because of emerging resistance.
Our results highlight the presence and spread of bla CTX-
M in the community and confirm that CTX-M-producing
Escherichia coli is the most frequent bacterial species iso-
lated in the community. These findings underline the need
for the rational use of antibiotics as well as for infection
control measures. The implementation in Cameroon or in
other African countries of methods of screening ESBL-
producing organisms in routine laboratories is of great
importance in order for us to offer patients appropriate
treatment and for infection control efforts to succeed. We
believe that our results could provide useful information
for clinical purposes and in the fight against bacterial resis-
tance to antibiotics in Cameroon.
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